An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2018
At a glance
- Drugs AAV-REP1 (Primary)
- Indications Choroideraemia
- Focus Therapeutic Use
- Acronyms REGENERATE; REGENERATE
- 04 Oct 2018 Status changed from active, no longer recruiting to recruiting.
- 09 Mar 2018 New trial record
- 13 Dec 2017 Status changed to active, no longer recruiting.